Company Profile
Medpace Stock Price, News & Catalysts
- Ticker:
- MEDP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
597.12 USD (+3.22%)
Close
Last updated: August 17, 2026
12.7B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, MEDP closed up 3.22% at $597.12. No new same-company headline was identified in the current news window.
Company overview
Full-Service Clinical Research
Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies.
Therapeutic and Scientific Expertise
The company uses physician leadership and therapeutic-area specialists to support protocol design, regulatory planning, trial execution and data interpretation. This scientifically driven model is particularly relevant for emerging biotechnology sponsors with limited internal development infrastructure.
Integrated Trial Operations
Medpace offers project management, clinical monitoring, data management, biostatistics, medical writing, safety and laboratory services through an integrated operating model. Its global network allows sponsors to run multinational studies with a single primary CRO.
Future catalysts
- Medpace’s watchlist is backlog conversion, study-start momentum, and how biotech funding trends affect CRO demand. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Medpace (MEDP)?
Medpace (MEDP) most recently closed at 597.12 USD, a +3.22% move versus the previous session.
What is the market cap of Medpace (MEDP)?
Medpace currently has a market capitalization of 12.7B USD on BioPharmSignal.
What does Medpace do?
Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies. Therapeutic and Scientific Expertise The company uses physician leadership and therapeutic-area specialists to support protocol design, regulatory...
On which exchange is MEDP stock listed?
Medpace (MEDP) is associated with NASDAQ, United States, Biopharma.
What is Full-Service?
Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies.
Which conditions is Medpace targeting with Full-Service?
Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies. Therapeutic and Scientific Expertise The company uses physician leadership and therapeutic-area specialists to support protocol design, regulatory...
How does Medpace describe recent progress with Full-Service?
Medpace’s watchlist is backlog conversion, study-start momentum, and how biotech funding trends affect CRO demand. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
What is Clinical?
Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies.